Navigation Links
Nektar Presents Data Demonstrating Favorable Oral Bioavailability and Drug-Drug Interaction Profile for NKTR-118
Date:9/13/2009

ile in both formulations and demonstrating the bioequivalence of the oral tablet formulation to solution. In vitro studies demonstrated the high metabolic stability of NKTR-118 compared to naloxone. Results of in vitro testing indicate that NKTR-118 has a low potential for clinically important drug-drug interactions, thereby facilitating the combination of NKTR-118 with a wide range of drugs in clinical development.

NKTR-118 Phase 2 Clinical Trial Data to be presented in Oral Plenary Session at ACG 2009

Nektar also announced today that results from a separate Phase 2 clinical trial of NKTR-118 have been accepted for presentation at an oral plenary session of the American College of Gastroenterology (ACG) 2009 Annual Scientific Meeting to be held in San Diego on October 27, 2009. The data will be presented by Dr. Lynn Webster, medical director of Lifetree Clinical Research and lead clinical investigator of the Phase 2 trial.

Topline data from this Phase 2 study showed that NKTR-118 met the primary endpoint of increase in spontaneous bowel movements over the baseline period in a double-blind, randomized, placebo-controlled study in 208 patients with opioid-induced constipation, while preserving the analgesic effect of opioid by reducing the blood-brain barrier penetration.

Download Today's Data Presentations for NKTR-118

The poster presentations presented today at the ACCP 38th Annual Meeting (Poster Session 1, 6:00 - 8:00 PM Central time) can be found on Nektar's website at http://www.nektar.com/product_pipeline/cns_pain_oral_nktr-118and119.html

ACCP Poster #140: "NKTR-118, an oral peripheral opioid antagonist, has low potential for drug-drug interactions"

ACCP P
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
2. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
3. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
4. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
5. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
6. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
7. Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
8. Nektar Therapeutics Reports Second Quarter 2009 Financial Results
9. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
10. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
11. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... YORK, Dec. 15 Reportlinker.com announces ... available in its catalogue: ,, Boehringer ... http://www.reportlinker.com/p0168539/Boehringer-Ingelheim-GmbH-PharmaVitae-Profile.html ,, Introduction ,, ... performance for Boehringer Ingelheim in the Rx ... portfolio and pipeline analysis and assessment of ...
(Date:12/15/2009)... -- Reportlinker.com announces that a new ... its catalogue: ,, The Future ... to 2015, Competitive Benchmarking, Product Pipeline ... http://www.reportlinker.com/p0168102/The-Future-of-HIV-Therapeutics---Market-Forecasts-to-2015-Competitive-Benchmarking-Product-Pipeline-and-Deals-Analysis.html ,, Summary ... latest research "The Future of HIV ...
(Date:12/15/2009)... Belgium, Dec. 15 Ghent University Hospital ... world to pioneer radiotherapy treatments using arc therapy, ... and efficient RapidArc radiotherapy technology from Varian Medical ... patient was treated in just 75 seconds, over ... treatments. ,, "This treatment would have taken more ...
Breaking Medicine Technology:Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 2Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 3Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 4Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 5Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 6Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 7Reportlinker Adds The Future of HIV Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 2Reportlinker Adds The Future of HIV Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 3Reportlinker Adds The Future of HIV Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 4Reportlinker Adds The Future of HIV Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 5Reportlinker Adds The Future of HIV Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 6Reportlinker Adds The Future of HIV Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 7Reportlinker Adds The Future of HIV Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 8Reportlinker Adds The Future of HIV Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 9Reportlinker Adds The Future of HIV Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 10Reportlinker Adds The Future of HIV Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 11Reportlinker Adds The Future of HIV Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 12European Radiotherapy Pioneers Deliver First Varian RapidArc(TM) Treatment for Rectal Carcinoma Patient 2European Radiotherapy Pioneers Deliver First Varian RapidArc(TM) Treatment for Rectal Carcinoma Patient 3New Research Shows Over use of Asthma Rescue Inhalers Substantially Reduced Through Pharmacist initiated Physician Intervention 6226 1New Research Shows Over use of Asthma Rescue Inhalers Substantially Reduced Through Pharmacist initiated Physician Intervention 6226 2New Research Shows Over use of Asthma Rescue Inhalers Substantially Reduced Through Pharmacist initiated Physician Intervention 6226 3Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology 6223 1Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology 6223 2Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology 6223 3Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology 6223 4Lexicon Announces Positive Phase 2 Results of LX1031 in Non Constipating Irritable Bowel Syndrome 6220 1Lexicon Announces Positive Phase 2 Results of LX1031 in Non Constipating Irritable Bowel Syndrome 6220 2Lexicon Announces Positive Phase 2 Results of LX1031 in Non Constipating Irritable Bowel Syndrome 6220 3Lexicon Announces Positive Phase 2 Results of LX1031 in Non Constipating Irritable Bowel Syndrome 6220 4Lexicon Announces Positive Phase 2 Results of LX1031 in Non Constipating Irritable Bowel Syndrome 6220 5
... Nov. 24 A new cancer treatment is,realizing ... treatment, a patient,s large, stage 4 tumor was ... of treatment, it no longer could be definitely,identified ... to nine months,after diagnosis. NeoPlas Innovation,s combination of ...
... moderate to severe acute pain and their health-care providers will ... Johnson Pharmaceutical Research & Development, L.L.C., (J&JPRD), announced that the ... for the relief of moderate to severe acute pain in ... , Tapentadol is a new centrally acting ...
Other Medicine Technology:New Cancer Treatment Shrinks Pancreatic Tumor 2FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain 2FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain 3FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain 4FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain 5FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain 6
(Date:12/15/2009)... suicide goes up within a week of getting ... News) -- Emotional stress can put newly diagnosed ... events and suicide, a new study has found. ... diagnosed with prostate cancer between 1961 and 2004. ... cardiovascular event within a year of cancer diagnosis ...
(Date:12/15/2009)... R.I., Dec. 15 Mergers and acquisitions ... expand their reach globally or complete a product ... the integration of safety programs. ,, A new ... Best Practices in a Hearing Conservation Program: US ... Airways and America West led the newly formed ...
(Date:12/15/2009)... by the Technology-based Learning SIG of ASTD,s Atlanta ... eLearning designs. This year nominees, eleven (11) ... The Venza Group entry, a highly engaging modular ... selected as the winner of the "Greater Than ... panel of distinguished judges. While announcing the ...
(Date:12/15/2009)... Inhibiting fatty acid synthesis in brain cancer cells may ... of deadly glioblastomas that are driven by amplified signaling ... a first-of-its-kind study by researchers at UCLA,s Jonsson Comprehensive ... acids for the formation of new membranes. The fatty ... cancer cells, and may be important for regulating cell ...
(Date:12/15/2009)... scientists have found the first potential immunological clue of ... the pandemic H1N1 virus. , The study analyzed ... 15 outpatients and 15 control subjects in 10 Spanish ... August 2009. Researchers from the Hospital Clinico Universitario de ... high levels of a molecule called interleukin 17 in ...
Breaking Medicine News(10 mins):Health News:New White Paper Details Best Practices of an Occupational Hearing Conservation Program: US Airways 2Health News:New White Paper Details Best Practices of an Occupational Hearing Conservation Program: US Airways 3Health News:New White Paper Details Best Practices of an Occupational Hearing Conservation Program: US Airways 4Health News:The Venza Group Received Top Honors at the American Society of Training & Development (ASTD) eLearning Excellence Awards Ceremony Held on December 10, 2009 2Health News:Targeting brain cancer cell metabolism may provide new treatment 2Health News:Targeting brain cancer cell metabolism may provide new treatment 3Health News:First immunological clue to why some H1N1 patients get very ill or die 2
... According to a Norwegian study of 1656 subjects over an ... in the workplace is linked to a significant increase in ... and its surroundings were enrolled in 1985 and asked about ... asthma. ,Then, after 5 years 1656 of the ...
... type 2 diabetes. According to a new survey, they showed ... been selected for a pancreas transplant.// Obesity is a strong ... the immune system destroys the insulin-producing cells of the pancreas. ... insulin, usually in the middle age. ,Pancreas transplantation, ...
... preserve their voice box. Treatment for laryngeal cancer often includes ... to learn to speak through an opening made in the ... that has a drastic impact on the quality of that ... been looking into other treatment approaches for laryngeal cancer. In ...
... is a slow killer that ticks away in one out ... These were among the facts and figures trotted out on ... Day. Gathered in front of the Victoria Statue, Cubbon Park, ... the City Police, and the Bangalore Metropolitan Transport Corporation (BMTC). ...
... Stress on human life has been increasing day by day.It ... a more healthy and peaceful life style.//This article is ... get angry for trivial things which does not concern us.But ... life threatning cardiac arrest in patients with heart disease by ...
... there's a firm connection between viral infection and pre-cancerous lesions ... human papillomavirus (HPV)// may increase the risk of cervical cancer. ... history of abnormal cervical cell growth were followed for ten ... another two years later. Those who were free of HPV ...
Other Medicine News:
The Escape Basket offers a side-by-side approach, unique to the market, for using a nitinol basket and holmium laser fiber together-providing physician control and independent manipulation of both th...
Simple, Effective Laparoscopic Irrigation Pumps from the Market Leader...
The Surgiflex WAVE XP couples the state-of-the-art Surgiflex WAVE Probe with the convenience of a truly portable battery-powered pump....
... is a minimally invasive, highly effective surgical ... incontinence. GYNECARE TVT is positioned close to ... and when needed, TVT provides tension-free support ... The procedure takes approximately 20 to 30 ...
Medicine Products: